Psilocybin-Assisted Therapy in Orlando, FL: the science, honestly
If you’re looking into psilocybin-assisted therapy in Orlando, you’re in good company — and the interest is grounded in real science, not hype. Over the past decade, psychedelic-assisted therapy research has moved from the fringes into leading universities, and psilocybin in particular has emerged as one of the most studied approaches for people facing depression, anxiety, PTSD, and the kind of existential distress that conventional treatment doesn’t always reach. This page is an honest, clinically-informed look at what the research does and doesn’t show. We do not offer or administer psilocybin. As of 2026 it is not legal for clinical use in Florida outside of authorized research.
This page is educational. Achieve Growth Therapy does not offer psilocybin-assisted therapy and does not administer psilocybin.
People in Orlando and across Florida often search for psilocybin-assisted therapy because they have heard about the research and want a clear account of what it is — and what it isn’t. Below is a clinically-informed overview of the science, typical research protocols, and the legal limits in Florida in 2026.
Important note: As of 2026, psilocybin remains a Schedule I controlled substance at the federal level. Florida does not currently have a legal framework for therapeutic psilocybin use outside of clinical research settings. We do not administer psilocybin. We do not offer psilocybin-assisted therapy as a clinical service.
Ketamine-assisted psychotherapy is available in Orlando and by telehealth across Florida
If you want a legal, clinic-based psychedelic-informed option now, Achieve Growth Therapy offers ketamine-assisted psychotherapy in Orlando and by telehealth across Florida. Medical evaluation and prescribing are handled by Journey Clinical. The therapy relationship stays with your clinician.
Read about ketamine-assisted psychotherapyWhat you’ll learn
- 01What Is Psilocybin-Assisted Therapy?
- 02What Does the Research Show?
- 03How Does Psilocybin Work in the Brain?
- 04What Do Research Protocols Typically Look Like?
- 05Who Has Been Studied — and Who Has Not
- 06The Legal Landscape in Florida (2026)
- 07How to Evaluate Information and Providers
- 08Why Integration Shows Up So Often in the Research
- 09Frequently Asked Questions
What Is Psilocybin-Assisted Therapy?
Psilocybin is a naturally occurring psychedelic compound found in certain species of fungi — commonly called “magic mushrooms.” When ingested, it converts to psilocin in the body and produces shifts in perception, emotion, and cognition that can last four to six hours. In research settings, these experiences are carefully structured and supported by trained clinicians.
In the published literature, psilocybin-assisted therapy is not the same as recreational use. Studies typically describe three phases:
- Preparation sessions — building alliance, setting intentions, screening for contraindications
- The dosing session — taking psilocybin in a supported, clinically supervised research environment
- Integration sessions — making meaning of the experience and translating insights into lasting change
The therapy component is not incidental. Research consistently suggests that the quality of the therapeutic relationship and the integration work after the experience matter as much as the experience itself.
Psilocybin vs. Other Compounds in the Research
Psilocybin is one of several substances being studied in psychedelic-assisted therapy research. Others include MDMA (studied in clinical trials for PTSD), ketamine (legal and available in many clinical settings, including as ketamine-assisted psychotherapy), LSD, and ayahuasca. Each has a distinct mechanism, risk profile, duration, and research base. Psilocybin’s relatively short duration (4–6 hours vs. 12+ for LSD or ayahuasca), its comparatively favorable physiological safety profile, and the volume of clinical research behind it are why it appears so often in the literature. None of this makes it a current clinical offering in Florida outside authorized research.
What Does the Research Show?
The past decade has produced a substantial body of peer-reviewed research on psilocybin. Here is a summary of some of the strongest evidence to date:
Treatment-Resistant Depression
Studies at Johns Hopkins University, Imperial College London, and NYU have reported significant reductions in depressive symptoms following psilocybin-assisted therapy in research protocols, including among people who had not responded to multiple antidepressant treatments. A large 2021 Phase IIb trial found that a 25mg dose produced significant symptom reduction in treatment-resistant depression, with a durable response measured at 12 weeks.
End-of-Life Anxiety and Existential Distress
Some of the earliest modern research focused on patients facing terminal illness. Studies at NYU and Johns Hopkins found that psilocybin-assisted therapy in those protocols reduced anxiety, depression, and demoralization in cancer patients — with effects reported at six-month and longer follow-ups, unusual durability for a small number of sessions.
Addiction
Preliminary research suggests psilocybin may help interrupt addictive patterns for alcohol and tobacco use. A 2022 double-blind randomized controlled trial published in JAMA Psychiatry found that psilocybin-assisted therapy reduced heavy drinking days compared with an active placebo. Earlier open-label work at Johns Hopkins reported high rates of tobacco abstinence at six months. These findings are promising and still early.
PTSD and Trauma
MDMA-assisted therapy currently has a larger research base for PTSD specifically. Psilocybin’s proposed mechanism — reducing default mode network rigidity, increasing neuroplasticity, and facilitating emotional processing — is why researchers continue to study it for trauma. That work is ongoing. MDMA is not a service offered here.
The science is promising, but it is not settled. Psilocybin therapy is not a cure, and it is not appropriate for everyone. Screening, preparation, and integration are essential components of the research protocols that produced these results.
How Does Psilocybin Work in the Brain?
Psilocybin works primarily by binding to serotonin 2A (5-HT2A) receptors, particularly in the prefrontal cortex. Researchers describe a cascade of effects that may be relevant to its therapeutic potential in studies:
Reduced Default Mode Network Activity
The default mode network (DMN) is a collection of brain regions associated with self-referential thinking — the constant mental chatter about the past, the future, and our sense of self. In depression and anxiety, the DMN tends to be overactive and rigid. Psilocybin temporarily quiets the DMN, which many study participants describe as a sense of liberation from rumination and a feeling of expanded perspective.
Increased Neuroplasticity
Studies using neuroimaging and animal models suggest that psilocybin promotes the growth of new synaptic connections and may increase BDNF (brain-derived neurotrophic factor). This window of plasticity following a psilocybin experience is one reason researchers emphasize integration in the days and weeks after a session. The brain appears more malleable, more open to new patterns of thinking and relating.
Emotional Processing
Psilocybin tends to reduce the amygdala’s reactivity to negative stimuli, which may help people approach previously avoided emotional material with less fear. Participants commonly report being able to revisit difficult memories or feelings with a sense of distance — as if watching their own story from a new vantage point.
The Mystical Experience
One of the more unexpected findings in psilocybin research is that the intensity of a “mystical-type experience” — characterized by a sense of unity, sacredness, noetic quality, and transcendence — is predictive of positive outcomes in several studies. This is not a fringe claim; it appears across multiple research sites and has been measured using validated instruments like the Mystical Experience Questionnaire. Researchers don’t fully understand why this is the case, but it has become part of the scientific literature.
What Do Research Protocols Typically Look Like?
Specific protocols vary by study. The outline below describes what most published psilocybin-assisted therapy trials have looked like. It is not a description of a service available at Achieve Growth Therapy.
Preparation (often 2–4 sessions)
Before any psilocybin is administered in a trial, participants typically spend time with the research therapists. Those sessions usually include:
- Building trust and therapeutic alliance
- Setting intentions
- Education about what to expect physically and psychologically
- Screening for contraindications such as personal or family history of psychosis, current use of certain medications (especially lithium and some antidepressants), or cardiovascular conditions
- Developing ways to work with difficult moments during the experience
The dosing session in research settings
In research settings, dosing sessions are carefully controlled. Participants typically arrive at a comfortable room, ingest psilocybin in capsule form, and use eye shades and selected music to support an inward focus. One or two trained therapists are present throughout. Sessions last approximately six to eight hours.
The experience is different for everyone. Some people encounter vivid imagery, emotional release, or a sense of interconnectedness. Others encounter confronting material — what researchers call challenging experiences — that, with support, can still be associated with benefit in studies. That is why preparation and the therapeutic container matter so much in the published protocols.
Integration in the research protocols
Integration is where much of the lasting work is thought to happen. The experience itself is catalytic — it can loosen fixed patterns and bring material to the surface. Integration sessions in trials help participants make meaning of what arose and consider whether anything in daily life actually changes once the feeling fades.
Without that follow-through, benefits reported in studies tend to be shorter-lived. With it, some trials report changes that persist for months.
Who Has Been Studied — and Who Has Not
Psilocybin-assisted therapy in research is not for everyone. The points below come from typical trial inclusion and exclusion criteria. They are not an invitation to treatment at this practice.
Conditions studied in published trials
- Treatment-resistant depression
- Major depressive disorder
- Anxiety, including end-of-life anxiety
- PTSD and trauma-related conditions (more limited evidence than for MDMA)
- Alcohol and tobacco use
- OCD (emerging research)
Common exclusions in research
Trials typically exclude people with:
- Personal or family history of schizophrenia, psychosis, or bipolar I disorder
- Active suicidal ideation with intent or plan
- Current use of lithium (seizure risk) or MAOIs
- Certain cardiovascular conditions
- Pregnancy
High doses of SSRIs may blunt the effects of psilocybin. This is an active area of discussion. Any medication change belongs with a prescribing physician — not with a web page.
What studies tend to emphasize about readiness
Beyond medical criteria, research teams look at whether someone can tolerate emotional disruption and is willing to do the work around the session, not only the session itself. Reasonable expectations matter: the literature treats this as a tool inside a protocol, not a standalone solution.
The Legal Landscape in Florida (2026)
This is the question most people actually need answered first.
At the federal level, psilocybin remains a Schedule I controlled substance under the Controlled Substances Act. It is illegal to manufacture, distribute, or possess psilocybin outside of DEA-authorized research settings.
Florida does not currently have a therapeutic psilocybin framework. Oregon and Colorado have passed legislation creating regulated access, but those systems are not available to Florida residents without traveling. City-level decriminalization elsewhere is not the same as legal therapeutic access.
Some people travel to jurisdictions where regulated or retreat-based experiences exist. That is a legal and personal decision outside this practice. We do not arrange, recommend, or supervise dosing in those settings.
What Achieve Growth Therapy actually offers
We do not administer psilocybin. We do not offer psilocybin-assisted therapy. Within Florida law, the current clinical offering in this area is:
- Ketamine-assisted psychotherapy in Orlando and by telehealth across Florida, with Journey Clinical providing medical evaluation and prescribing
- Ordinary psychotherapy that can include honest conversation about psychedelic research, without crossing into facilitating illegal use
If you came here looking for a legal option now, start with ketamine-assisted psychotherapy rather than this page.
How to Evaluate Information and Providers
Not everyone using the language of “psychedelic therapy” has clinical credentials, specialized training, or a clear account of what is legal in Florida. Questions worth asking of any source:
- Are they a licensed mental health professional or physician?
- Have they completed specialized training in psychedelic-assisted therapy research frameworks?
- Are they transparent about what is legal in Florida and what is not?
- Do they treat integration as part of the work, not an afterthought?
- Do they minimize risk or rush past screening?
Be cautious of anyone who suggests they can administer psilocybin in Florida outside of a clinical trial. That is not something this practice does.
Why Integration Shows Up So Often in the Research
Across studies, the experience is treated as a catalyst, not the whole treatment. Integration is the work of asking what, if anything, is different in a typical week once the feeling is gone.
In the literature, that work often includes:
- Meaning-making — themes, images, and feelings, and what they might mean in ordinary life
- Somatic work — what the body is still holding after the session
- Relational change — how someone shows up with other people once the intensity fades
- Behavioral change — habits, boundaries, and choices that either move or stay the same
- Existential material — unusual or mystical-type experiences, without inflating them into a guarantee
Many of the more durable findings in the research come from that follow-through, not from the hours of the dosing session alone.
Frequently Asked Questions
Do you offer psilocybin-assisted therapy in Orlando?
No. As of 2026, psilocybin is not legal for clinical use in Florida outside authorized research. Achieve Growth Therapy does not administer psilocybin and does not offer psilocybin-assisted therapy. The legal clinical option we offer is ketamine-assisted psychotherapy.
Is psilocybin therapy safe?
Physiologically, psilocybin has a relatively favorable safety profile in research settings. It is not considered addictive in the way many other substances are, and organ toxicity is low. The primary risks discussed in the literature are psychological: difficult experiences, the rare unmasking of latent psychiatric conditions in high-risk people, and use without screening or support. That is why trials put so much weight on screening and preparation.
How long do the effects last?
The acute experience typically lasts four to six hours. Some studies report therapeutic changes lasting months. Those results come from protocols that included preparation and integration, not from the compound alone.
Will insurance cover psilocybin therapy?
No. Because psilocybin remains Schedule I federally, it is not an insured clinical service. Ordinary psychotherapy with a licensed clinician may be covered depending on the plan and diagnosis codes. That is a separate question from psilocybin itself.
What about antidepressants?
SSRIs may blunt the acute effects of psilocybin. Stopping antidepressants abruptly is not recommended. Medication changes belong with a prescribing physician.
What do studies say about difficult experiences?
Challenging experiences are fairly common in trials and are not automatically treated as failures. In research protocols they are sometimes associated with later benefit when well supported. The factors the literature keeps returning to are a safe setting, trained support, enough preparation, and less fighting the experience mid-session.
Is there a clinical trial near Orlando?
Trials open and close. The public listing is ClinicalTrials.gov. Search for “psilocybin” and filter by location. Listing a trial here would go stale quickly, so we point to the registry instead of naming specific studies or sponsors.
The legal option we offer is ketamine-assisted psychotherapy.
This page is here so the science is stated clearly. If you are looking for treatment in Orlando or by telehealth across Florida, start with ketamine-assisted psychotherapy. Medical evaluation and prescribing are through Journey Clinical. We also offer therapy for depression, anxiety therapy, and other psychotherapy.
We take the research seriously. We also stay inside Florida law.
Learn about ketamine-assisted psychotherapy